Avelumab plus cetuximab versus cetuximab alone in metastatic colorectal cancer patients
Adding avelumab to cetuximab helps only a specific subgroup of colorectal cancer patients
This randomized phase II trial evaluated adding avelumab to cetuximab in RAS/BRAF wild-type metastatic colorectal cancer patients. The combi…
A new trial shows adding avelumab to cetuximab improves survival only for patients without certain genetic changes, not for everyone.
SCOPE platform predicts outcomes for metastatic colorectal and pancreatic cancers using organoid screening.
A Lab-Built Tumor Test May Predict If Cancer Drugs Will Work
This preclinical platform development study utilized a machine learning system integrating patient-derived organoids and clinical data to pr…
A platform called SCOPE uses tiny lab-grown copies of a patient's tumor to predict — before a large trial even starts — whether a cancer dru…
Sequential cetuximab-bevacizumab vs bevacizumab-EGFR mAb shows no DDC difference in metastatic CRC
New Drug Order Doesn't Beat Old Standard
A phase III randomized controlled trial in 263 untreated, unresectable wild-type RAS/BRAF metastatic colorectal cancer patients found no dif…
A new drug order for advanced colon cancer did not improve disease control or survival compared to the standard treatment sequence.
Early pilot feasibility report on deep longitudinal profiling in metastatic cancer patients
Early pilot study tests data collection methods for cancer patients
This prospective, multicenter observational study protocol and feasibility report describes an early internal pilot involving 30 female pati…
Researchers enrolled 30 women with newly diagnosed metastatic breast, lung, or colorectal cancer to test how well they could gather long-ter…
Trifluridine/tipiracil plus irinotecan and bevacizumab in metastatic colorectal cancer resistant to prior chemotherapy
A New Second-Line Combo Shows Promise for Advanced Colon Cancer
This multicenter, single-arm, phase II trial evaluated biweekly trifluridine/tipiracil, irinotecan, and bevacizumab in 60 patients with meta…
For patients whose advanced colon cancer has stopped responding to initial chemo, a new drug combination is showing it can effectively fight…
Nomogram predicts moderate-to-severe complications after primary tumor resection in metastatic colorectal cancer
Study identifies four factors linked to surgical complications in metastatic colorectal cancer
A retrospective single-institution cohort study of 404 metastatic colorectal cancer patients undergoing primary tumor resection identified a…
Older age, low albumin, tumor location, and long surgery time raise complication risks for metastatic colorectal cancer patients.
Anti-EGFR rechallenge improves response and PFS but not OS in ctDNA wild-type chemorefractory mCRC
Anti-EGFR rechallenge shows benefit for some advanced colorectal cancer patients
A meta-analysis of three phase II randomized trials (n=320) in pretreated ctDNA RAS/BRAF wild-type mCRC found anti-EGFR rechallenge signific…
Giving anti-EGFR drugs again helps some advanced colorectal cancer patients shrink tumors and delay growth, though it does not extend overal…
Post hoc analysis links TMB ≥9 or BRAF-V600E to longer PFS with chemo-nivolumab in MSS/pMMR mCRC
Could two simple blood tests help predict which colon cancer patients benefit from immunotherapy?
A post hoc analysis of the METIMMOX RCT in patients with metastatic MSS/pMMR colorectal cancer found that in the experimental arm (alternati…
Two simple blood tests and tumor markers can predict which colon cancer patients live longer on immunotherapy combined with chemotherapy.